Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.

about

Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.

Item

http://www.wikidata.org/entity/Q48139344

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Novel agent-based salvage auto ...... for relapsed multiple myeloma.

@en

Novel agent-based salvage auto ...... for relapsed multiple myeloma.

@nl

type

Item

label

Novel agent-based salvage auto ...... for relapsed multiple myeloma.

@en

Novel agent-based salvage auto ...... for relapsed multiple myeloma.

@nl

prefLabel

Novel agent-based salvage auto ...... for relapsed multiple myeloma.

@en

Novel agent-based salvage auto ...... for relapsed multiple myeloma.

@nl

P1476

Novel agent-based salvage auto ...... for relapsed multiple myeloma.

@en

P2093

Annalisa Pezzi

http://www.w3.org/2001/XMLSchema#string

Beatrice Anna Zannetti

http://www.w3.org/2001/XMLSchema#string

Claudia Cellini

http://www.w3.org/2001/XMLSchema#string

Elena Zamagni

http://www.w3.org/2001/XMLSchema#string

Ilaria Rizzello

http://www.w3.org/2001/XMLSchema#string

Isola Caratozzolo

http://www.w3.org/2001/XMLSchema#string

Lucia Pantani

http://www.w3.org/2001/XMLSchema#string

Paola Tacchetti

http://www.w3.org/2001/XMLSchema#string

Patrizia Tosi

http://www.w3.org/2001/XMLSchema#string

Serena Rocchi

http://www.w3.org/2001/XMLSchema#string

P2860

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.

Salvage second hematopoietic cell transplantation in myeloma

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Durable remission with salvage second autotransplants in patients with multiple myeloma.

P304

2071-2078

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-3140-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29063955

http://www.w3.org/2001/XMLSchema#string